Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Geron Corporation Reports Second Quarter 2017 Financial Results


Posted on: 09 Aug 17

MENLO PARK, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the three and six months ended June 30, 2017.

For the second quarter of 2017, the company reported a net loss of $6.4 million, or $0.04 per share, compared to $8.6 million, or $0.05 per share, for the comparable 2016 period. Net loss for the first six months of 2017 was $13.6 million, or $0.09 per share, compared to $17.5 million, or $0.11 per share, for the comparable 2016 period. The company ended the second quarter of 2017 with $117.2 million in cash and investments.

Revenues for the three and six months ended June 30, 2017 were $174,000 and $711,000, respectively, compared to $211,000 and $960,000 for the comparable 2016 periods. Revenues for the three and six month periods ending June 30, 2017 and 2016 included royalty and license fee revenues under various non-imetelstat license agreements.

Total operating expenses for the three and six months ended June 30, 2017 were $6.9 million and $14.9 million, respectively, compared to $9.1 million and $18.9 million for the comparable 2016 periods. Research and development expenses for the three and six months ended June 30, 2017 were $2.5 million and $5.9 million, respectively, compared to $4.6 million and $9.6 million for the comparable 2016 periods. The decrease in research and development expenses for the three and six month periods ending June 30, 2017, compared to the same periods in 2016, primarily reflects lower costs for the proportionate share of clinical development expenses under the collaboration with Janssen Biotech, Inc. and reduced personnel related expenses. General and administrative expenses for the three and six months ended June 30, 2017 were $4.4 million and $9.1 million, respectively, compared to $4.5 million and $9.3 million for the comparable 2016 periods. The decrease in general and administrative expenses for the three and six month periods ending June 30, 2017, compared to the same periods in 2016, primarily reflects lower consulting costs.

Interest and other income for the three and six months ended June 30, 2017 was $346,000 and $678,000, respectively, compared to $293,000 and $549,000 for the comparable 2016 periods. The increase in interest and other income for the three and six month periods ending June 30, 2017, compared to the same periods in 2016, primarily reflects higher yields on the company’s marketable securities portfolio.

Due to the recent announcement and conference call on updates to the clinical development plans for imetelstat, Geron’s management will not be hosting a separate conference call in connection with these financial results.

About Geron

Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

Financial table follows.

GERON CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
 
  Three Months EndedSix Months Ended
  June 30,June 30,
(In thousands, except share and per share data) 2017  2016  2017  2016 
      
Revenues:     
  License fees and royalties  $174  $211  $711  $960 
          
Operating expenses:         
  Research and development   2,499   4,575   5,873   9,608 
  General and administrative      4,406      4,547      9,063      9,340 
Total operating expenses      6,905      9,122      14,936      18,948 
Loss from operations  (6,731)  (8,911)  (14,225)  (17,988)
          
Interest and other income   346   293   678   549 
Interest and other expense     (20)       (19)       (41)       (40)
Net loss  $   (6,405) $  (8,637) $   (13,588) $   (17,479)
                
Basic and diluted net loss per share:         
  Net loss per share  $   (0.04) $   (0.05) $   (0.09) $   (0.11)
  Shares used in computing net loss per share   159,182,367    158,998,931   159,171,959   158,947,485 


CONDENSED BALANCE SHEETS
    
  June 30,December 31,
(In thousands) 20172016
  (Unaudited)(Note 1)
Current assets:   
Cash, cash equivalents and restricted cash  $6,874$13,078
Current marketable securities  88,239 102,035
Other current assets         6,953    999
Total current assets   102,066 116,112
      
Noncurrent marketable securities   22,076 13,954
Property and equipment, net      140   183
  $  124,282$130,249
      
Current liabilities  $11,274$7,869
Stockholders’ equity   113,008 122,380
  $124,282$130,249

Note 1: Derived from audited financial statements included in the company’s annual report on Form 10-K for the year ended December 31, 2016.

GlobeNewswire
globenewswire.com

Last updated on: 10/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.